ECSP066710A - Mutantes de anticuerpo anti-cd40 - Google Patents

Mutantes de anticuerpo anti-cd40

Info

Publication number
ECSP066710A
ECSP066710A EC2006006710A ECSP066710A ECSP066710A EC SP066710 A ECSP066710 A EC SP066710A EC 2006006710 A EC2006006710 A EC 2006006710A EC SP066710 A ECSP066710 A EC SP066710A EC SP066710 A ECSP066710 A EC SP066710A
Authority
EC
Ecuador
Prior art keywords
adcc
mutants
cdc activities
mutation
substitution
Prior art date
Application number
EC2006006710A
Other languages
English (en)
Inventor
Nobuaki Takahashi
Toru Miura
Yoshinor Kitigawa
Aki Hirano
Original Assignee
Kirin Brewery
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kirin Brewery filed Critical Kirin Brewery
Publication of ECSP066710A publication Critical patent/ECSP066710A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se pretende proporcionar mutantes de un anticuerpo anti-CD40, el cual se espera como terapéuticamente eficaz, que sea optimizado como un fármaco al reducir las actividades de ADCC y CDC del mismo. Particularmente, un mutante de anticuerpo monoclonal anti-CD40 agonista en donde al menos la región de articulación es una región de articulación que se origina en la IgG2 humana y la cual tiene una mutación y/o una sustitución de uno o más aminoácidos que provoca la reducción en las actividades de ADCC y/o CDC en la región constante; y un mutante de anticuerpo anti-CD40 antagonista el cual tiene al menos una mutación y/o la sustitución que provoca la reducción en las actividades de ADCC y/o CDC en la región constante.
EC2006006710A 2003-12-25 2006-07-19 Mutantes de anticuerpo anti-cd40 ECSP066710A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003431408 2003-12-25
PCT/JP2004/019750 WO2005063981A1 (ja) 2003-12-25 2004-12-24 抗cd40抗体の変異体

Publications (1)

Publication Number Publication Date
ECSP066710A true ECSP066710A (es) 2006-11-24

Family

ID=34736433

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2006006710A ECSP066710A (es) 2003-12-25 2006-07-19 Mutantes de anticuerpo anti-cd40

Country Status (24)

Country Link
US (4) US8568725B2 (es)
EP (1) EP1707627B1 (es)
JP (2) JP4242388B2 (es)
KR (2) KR101200188B1 (es)
CN (1) CN1922316B (es)
AU (1) AU2004309275B2 (es)
BR (1) BRPI0417266B8 (es)
CA (1) CA2551008C (es)
CY (1) CY1114019T1 (es)
DK (1) DK1707627T3 (es)
EC (1) ECSP066710A (es)
ES (1) ES2397631T3 (es)
HR (1) HRP20130078T1 (es)
IL (1) IL176508A (es)
NO (1) NO344608B1 (es)
NZ (1) NZ548325A (es)
PL (1) PL1707627T3 (es)
PT (1) PT1707627E (es)
RU (1) RU2377254C2 (es)
SI (1) SI1707627T1 (es)
TW (1) TW200540186A (es)
UA (1) UA93027C2 (es)
WO (1) WO2005063981A1 (es)
ZA (1) ZA200605874B (es)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
US20080199471A1 (en) * 2002-03-01 2008-08-21 Bernett Matthew J Optimized cd40 antibodies and methods of using the same
US8277810B2 (en) 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
CN1922316B (zh) 2003-12-25 2011-03-23 协和发酵麒麟株式会社 抗cd40抗体突变体
US8716451B2 (en) 2005-01-12 2014-05-06 Kyowa Hakko Kirin Co., Ltd Stabilized human IgG2 and IgG3 antibodies
US20110123440A1 (en) * 2005-03-29 2011-05-26 Genevieve Hansen Altered Antibody FC Regions and Uses Thereof
AU2006232287B2 (en) 2005-03-31 2011-10-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
JP4294082B2 (ja) * 2006-03-23 2009-07-08 協和発酵キリン株式会社 ヒトトロンボポエチン受容体に対するアゴニスト抗体
EP2009101B1 (en) 2006-03-31 2017-10-25 Chugai Seiyaku Kabushiki Kaisha Antibody modification method for purifying bispecific antibody
CN104761637B (zh) 2006-03-31 2021-10-15 中外制药株式会社 调控抗体血液动力学的方法
GB0620894D0 (en) * 2006-10-20 2006-11-29 Univ Southampton Human immune therapies using a CD27 agonist alone or in combination with other immune modulators
EP2125893A2 (en) * 2007-01-23 2009-12-02 Xencor, Inc. Optimized cd40 antibodies and methods of using the same
JP5331100B2 (ja) * 2007-04-25 2013-10-30 イミュアールエックス・インコーポレーテッド Ｎｋｔアクチベータ、ｃｄ４０アゴニスト、及び任意選択的に抗原を含んでなるアジュバント組合せと、細胞性免疫において相乗的な増強を誘導するためのその使用
WO2009041734A1 (ja) * 2007-09-26 2009-04-02 Kyowa Hakko Kirin Co., Ltd. ヒトトロンボポエチン受容体に対するアゴニスト抗体
ES2595638T3 (es) 2007-09-26 2017-01-02 Chugai Seiyaku Kabushiki Kaisha Método para modificar el punto isoeléctrico de un anticuerpo mediante la sustitución de aminoácidos en una CDR
KR101680906B1 (ko) 2007-09-26 2016-11-30 추가이 세이야쿠 가부시키가이샤 항체 정상영역 개변체
US9221914B2 (en) * 2007-12-26 2015-12-29 Biotest Ag Agents targeting CD138 and uses thereof
CN101965366B (zh) 2007-12-26 2016-04-27 生物测试股份公司 靶向cd138的免疫缀合物及其应用
CA2712989C (en) 2008-01-23 2015-10-27 Xencor, Inc. Optimized cd40 antibodies and methods of using the same
KR20160070165A (ko) 2008-02-08 2016-06-17 메디뮨 엘엘씨 Ｆｃ 리간드 친화성이 감소된 항-ＩＦＮＡＲ１ 항체
AR074438A1 (es) * 2008-12-02 2011-01-19 Pf Medicament Proceso para la modulacion de la actividad antagonista de un anticuerpo monoclonal
WO2010064090A1 (en) * 2008-12-02 2010-06-10 Pierre Fabre Medicament Process for the modulation of the antagonistic activity of a monoclonal antibody
AU2010222942B2 (en) 2009-03-10 2013-01-10 Baylor Research Institute Anti-CD40 antibodies and uses thereof
DK2406289T3 (en) 2009-03-10 2017-05-01 Baylor Res Inst ANTIGEN PRESENTING CELL TARGETED ANTIVIRUS VACCINES
JP5717624B2 (ja) 2009-03-19 2015-05-13 中外製薬株式会社 抗体定常領域改変体
EP2826789A1 (en) 2009-03-19 2015-01-21 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
ES2829423T3 (es) * 2009-04-20 2021-05-31 Kyowa Kirin Co Ltd Anticuerpo anti-CD40 que contiene IgG2 que presenta tres mutaciones de aminoácido introducidas en el mismo
JP2011041475A (ja) * 2009-08-19 2011-03-03 Asahi Kasei Medical Co Ltd 抗体製造方法
US10150808B2 (en) * 2009-09-24 2018-12-11 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant regions
WO2011108714A1 (ja) 2010-03-04 2011-09-09 中外製薬株式会社 抗体定常領域改変体
HUE049849T2 (hu) * 2010-03-31 2020-10-28 Boehringer Ingelheim Int Anti-CD40 antitestek
EP2625292B1 (en) 2010-10-07 2018-12-05 The General Hospital Corporation Biomarkers of cancer
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
JP5458188B2 (ja) * 2011-02-17 2014-04-02 協和発酵キリン株式会社 抗ｃｄ４０抗体の高濃度製剤
TR201909840T4 (tr) 2011-03-11 2019-07-22 Beth Israel Deaconess Medical Ct Inc Anti-CD40 antikorları ve kullanımları.
HUE038848T2 (hu) 2011-04-21 2018-11-28 Bristol Myers Squibb Co CD40-antagonista antitest polipeptidek
ES2709654T3 (es) 2011-04-29 2019-04-17 Apexigen Inc Anticuerpos anti-CD40 y métodos de uso
EP2718325A4 (en) 2011-06-13 2015-03-11 ABGENOMICS COöPERATIEF U A ANTI-PSGL-1 ANTIBODIES AND USES THEREOF
KR102100388B1 (ko) * 2012-02-06 2020-04-13 인히브릭스, 인크. Cd47 항체 및 그 사용 방법
KR102270618B1 (ko) 2012-10-30 2021-06-30 아펙시젠, 인코포레이티드 항-cd40 항체 및 사용 방법
PT3444271T (pt) 2013-08-08 2022-01-05 Inst Nat Sante Rech Med Modulocinas baseadas em il-15 e no domínio sushi de il-15ralfa
ES2881306T3 (es) 2013-09-27 2021-11-29 Chugai Pharmaceutical Co Ltd Método para la producción de heteromultímeros de polipéptidos
CN120939216A (zh) 2014-01-13 2025-11-14 贝勒研究院 抗hpv和hpv相关的疾病的新疫苗
EP3113796A1 (en) 2014-03-07 2017-01-11 Bristol-Myers Squibb Company Method of using antibody polypeptides that antagonize cd40 to treat ibd
AU2015237864B2 (en) * 2014-03-24 2020-12-03 Cancer Research Technology Limited Modified antibodies containing modified IgG2 domains which elicit agonist or antagonistic properties and use thereof
EP3161159B1 (en) 2014-06-25 2020-08-05 The General Hospital Corporation Targeting human satellite ii (hsatii)
WO2016011401A1 (en) * 2014-07-18 2016-01-21 Kedl Ross M Immunostimulatory combinations and use thereof
CN116059378A (zh) 2014-12-10 2023-05-05 明尼苏达大学董事会 用于治疗疾病的遗传修饰的细胞、组织和器官
JP7082484B2 (ja) 2015-04-01 2022-06-08 中外製薬株式会社 ポリペプチド異種多量体の製造方法
CN107810198B (zh) 2015-05-29 2021-09-03 艾伯维公司 抗cd40抗体及其用途
BR112018004296B1 (pt) 2015-09-04 2020-05-05 Primatope Therapeutics Inc anticorpos anti-cd40 humanizados e usos dos mesmos
BR112018006251A2 (pt) * 2015-09-30 2018-10-16 Janssen Biotech Inc anticorpos antagonistas que se ligam especificamente a cd40 humano e métodos de uso
AU2016381992B2 (en) 2015-12-28 2024-01-04 Chugai Seiyaku Kabushiki Kaisha Method for promoting efficiency of purification of Fc region-containing polypeptide
JP7178906B2 (ja) 2016-05-19 2022-11-28 ザ ジェネラル ホスピタル コーポレイション ナチュラルキラー細胞および制御性Ｔ細胞の活性を強化するためのプラットフォームである、その受容体ＩＬ－２Ｒβに繋ぎ止められたインターロイキン－２
BR112018074453A2 (pt) 2016-05-27 2019-03-19 Abbvie Biotherapeutics Inc. proteínas de ligação biespecíficas ligando uma protéina imunomoduladora e um antígeno tumoral
TWI761348B (zh) * 2016-05-27 2022-04-21 美商艾伯維生物醫療股份有限公司 抗cd40抗體及其用途
RU2769282C2 (ru) 2016-06-20 2022-03-30 Кимаб Лимитед Анти-PD-L1 и IL-2 цитокины
WO2018089688A1 (en) 2016-11-09 2018-05-17 Jinjun Shi Restoration of tumor suppression using mrna-based delivery system
WO2018106945A1 (en) 2016-12-07 2018-06-14 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
WO2018183929A1 (en) 2017-03-30 2018-10-04 Progenity Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
MX2019011986A (es) 2017-04-07 2019-11-07 Igm Biosciences Inc Regiones constantes de igm humana modificadas para la modulacion de la funcion efectora de la citolisis dependiente de complemento referencia cruzada a solicitudes relacionadas.
US10610585B2 (en) 2017-09-26 2020-04-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions for treating and preventing HIV
KR20200074993A (ko) 2017-11-03 2020-06-25 노파르티스 아게 쇼그렌 증후군 치료에 사용하기 위한 항-cd40 항체
CN109971721B (zh) * 2017-12-28 2023-10-31 上海细胞治疗研究院 自表达cd47抗体的间皮素特异性car-t细胞及其用途
CN109971725B (zh) 2017-12-28 2024-02-02 上海细胞治疗研究院 抗体修饰的嵌合抗原受体修饰t细胞及其用途
EP4317972A3 (en) 2018-02-06 2024-03-13 The General Hospital Corporation Repeat rna as biomarkers of tumor immune response
JP6861301B2 (ja) 2018-04-13 2021-04-21 ノバルティス アーゲー 移植片拒絶の予防に使用するための抗ｃｄ４０抗体
AU2019255781A1 (en) 2018-04-20 2020-10-29 Lyvgen Biopharma Holdings Limited Anti-CD40 antibodies and uses thereof
KR20210035805A (ko) 2018-06-15 2021-04-01 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 세포후 신호전달 인자의 조절을 통한 면역 활성의 증가
WO2019246317A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease or condition in a tissue originating from the endoderm
WO2019246312A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
WO2020014471A1 (en) 2018-07-11 2020-01-16 The Brigham And Women's Hospital, Inc. Methods and compositions for delivery of agents across the blood-brain barrier
CN112996818B (zh) * 2018-09-28 2022-06-21 礼进生物医药科技（上海）有限公司 具有经过工程化的Fc结构域的抗CD40结合分子及其治疗用途
JP7626698B2 (ja) * 2018-09-28 2025-02-04 リビジェン バイオファーマ ホールディングス リミテッド 操作されたＦｃドメインを有する抗ＣＤ４０結合分子およびその治療用途
EP3883635A1 (en) 2018-11-19 2021-09-29 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
BR112021009835A2 (pt) * 2018-11-30 2021-08-17 Jiangsu Hengrui Medicine Co., Ltd. anticorpo anti-cd40, fragmento de ligação ao antígeno e uso farmacêutico dos mesmos
CN113271964A (zh) 2019-01-11 2021-08-17 诺华股份有限公司 化脓性汗腺炎治疗中使用的抗cd40抗体
US20200318200A1 (en) 2019-04-02 2020-10-08 The Brigham And Women's Hospital, Inc. Methods for Identifying Progression of a Primary Melanoma
WO2020227159A2 (en) 2019-05-03 2020-11-12 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity
TWI875757B (zh) 2019-05-08 2025-03-11 瑞士商諾華公司 T1dm和胰島炎治療中使用之抗cd40抗體
CA3148890A1 (en) 2019-09-11 2021-03-18 Novartis Ag A method for preventing human virus associated disorders in patients
CN115666704B (zh) 2019-12-13 2025-09-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
US20230114107A1 (en) 2019-12-17 2023-04-13 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
CN115279400B (zh) 2020-01-10 2026-04-28 布里格姆妇女医院 用于跨血脑屏障递送免疫治疗剂以治疗脑癌的方法和组合物
US20230355804A1 (en) 2020-06-29 2023-11-09 Flagship Pioneering Innovations V, Inc. Viruses engineered to promote thanotransmission and their use in treating cancer
US20240101693A1 (en) * 2021-01-21 2024-03-28 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
AU2022214319A1 (en) 2021-01-28 2023-08-03 Regeneron Pharmaceuticals, Inc. Compositions and methods for treating cytokine release syndrome
EP4313109A1 (en) 2021-03-31 2024-02-07 Flagship Pioneering Innovations V, Inc. Thanotransmission polypeptides and their use in treating cancer
AU2022303363A1 (en) 2021-06-29 2024-01-18 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
US20240343817A1 (en) * 2021-07-14 2024-10-17 Staidson (Beijing) Biopharmaceuticals Co., Ltd. Antibody that specifically recognizes cd40 and application thereof
US12234294B2 (en) 2021-11-05 2025-02-25 Kiniksa Pharmaceuticals, Gmbh Pharmaceutical composition of a humanized anti-CD40 antibody
US20240174732A1 (en) 2022-10-05 2024-05-30 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer
WO2024151687A1 (en) 2023-01-09 2024-07-18 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer
WO2025184603A2 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. The use of cd40 inhibitors for inhibiting an immune response and enabling immunogen administration and re-administration
US20250276092A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
FI884924L (fi) * 1987-10-28 1989-04-29 Oncogen Humanimmuglobulin som producerats med hybrid-dna-teknik.
DE3737506A1 (de) 1987-11-05 1989-05-24 Ibm Deutschland Vorrichtung zur bestueckung insbesondere von leiterplatten
JPH0725784B2 (ja) 1989-09-14 1995-03-22 鐘紡株式会社 アルコール刺激臭暖和剤
AU707440B2 (en) 1994-03-29 1999-07-08 Celltech Therapeutics Limited Antibodies against E-selectin
US5683693A (en) * 1994-04-25 1997-11-04 Trustees Of Dartmouth College Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40
ES2230848T3 (es) * 1998-04-28 2005-05-01 Smithkline Beecham Corporation Anticuerpos monoclonales con inmunogenicidad reducida.
US6376653B1 (en) * 1998-09-28 2002-04-23 Smithkline Beecham Plc Tie2 antagonist antibodies
US6365154B1 (en) 1998-09-28 2002-04-02 Smithkline Beecham Corporation Tie2 agonist antibodies
EP1169352A4 (en) 1999-04-14 2005-05-04 Smithkline Beecham Corp ANTIBODY AGAINST THE ERYTHROPOIETIN RECEPTOR
US6998124B1 (en) * 1999-04-14 2006-02-14 Smithkline Beecham Corporation Erythropoietin receptor antibodies
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
US20030059427A1 (en) * 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
CA2658221C (en) 2001-04-27 2012-11-27 Kyowa Kirin Co., Ltd. Anti-cd40 monoclonal antibody
US7262278B2 (en) 2001-10-15 2007-08-28 Kirin Beer Kabushiki Kaisha Anti-HLA-DR antibody
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
CN1922316B (zh) * 2003-12-25 2011-03-23 协和发酵麒麟株式会社 抗cd40抗体突变体
JP5458188B2 (ja) * 2011-02-17 2014-04-02 協和発酵キリン株式会社 抗ｃｄ４０抗体の高濃度製剤

Also Published As

Publication number Publication date
NO20063197L (no) 2006-09-21
BRPI0417266B8 (pt) 2021-05-25
KR20060130615A (ko) 2006-12-19
ZA200605874B (en) 2008-04-25
NO344608B1 (no) 2020-02-10
EP1707627A1 (en) 2006-10-04
WO2005063981A1 (ja) 2005-07-14
HK1102134A1 (en) 2007-11-09
UA93027C2 (ru) 2011-01-10
US20140248266A1 (en) 2014-09-04
ES2397631T3 (es) 2013-03-08
CY1114019T1 (el) 2016-07-27
PT1707627E (pt) 2013-01-24
TW200540186A (en) 2005-12-16
TWI343389B (es) 2011-06-11
CA2551008A1 (en) 2005-07-14
US9598494B2 (en) 2017-03-21
JP4242388B2 (ja) 2009-03-25
AU2004309275B2 (en) 2010-12-23
US20140105907A1 (en) 2014-04-17
BRPI0417266B1 (pt) 2020-04-28
IL176508A (en) 2011-09-27
EP1707627B1 (en) 2012-11-14
SI1707627T1 (sl) 2013-02-28
KR101200188B1 (ko) 2012-11-13
NZ548325A (en) 2009-07-31
US8568725B2 (en) 2013-10-29
US20070148163A1 (en) 2007-06-28
EP1707627A4 (en) 2008-08-27
DK1707627T3 (da) 2012-12-17
AU2004309275A1 (en) 2005-07-14
BRPI0417266A (pt) 2007-03-13
JP2009022289A (ja) 2009-02-05
CN1922316B (zh) 2011-03-23
JPWO2005063981A1 (ja) 2007-07-19
RU2006126979A (ru) 2008-01-27
CA2551008C (en) 2013-10-01
US9023360B2 (en) 2015-05-05
HRP20130078T1 (hr) 2013-02-28
KR20120116018A (ko) 2012-10-19
PL1707627T3 (pl) 2013-04-30
KR101223373B1 (ko) 2013-01-16
US20150057437A1 (en) 2015-02-26
US9023361B2 (en) 2015-05-05
RU2377254C2 (ru) 2009-12-27
CN1922316A (zh) 2007-02-28
IL176508A0 (en) 2006-10-05

Similar Documents

Publication Publication Date Title
ECSP066710A (es) Mutantes de anticuerpo anti-cd40
CO6231009A2 (es) Anticuerpos ox40 antagonistas y su uso en el tratamiento de enfermedades inflamatorias y autoinmunes
HRP20181459T1 (hr) Humanizirani antagonisti anti-beta7 i njihove uporabe
PE20110802A1 (es) Un anticuerpo antagonista de pcsk9
CR9975A (es) Anticuerpos antagonistas dirigidos contra el péptido relacionado con el gen de calcitonina
CY1110759T1 (el) Παραλλαγες ανοσοσφαιρινων και χρησεις αυτων
DK1773885T3 (da) Humaniserede anti-c-met-antagonister
PE20081186A1 (es) Metodos y composiciones para el tratamiento de enfermedades alergicas
PE20081399A1 (es) Anticuerpos antagonistas anti-notch3 y su uso en la prevencion y el tratamiento de enfermedades relacionadas con el receptor notch3
PE20140882A1 (es) Anticuerpos neutralizantes de citomegalovirus humano
EA200300663A1 (ru) Антагонисты cxcr3
PE20060376A1 (es) ANTICUERPO MONOCLONAL HUMANIZADO O QUIMERICO COMO INHIBIDOR DE hIL-3
PE20140806A1 (es) Anticuerpos anti-factor d humanizados y sus usos
PE20211293A1 (es) Anticuerpos monoclonales antagonistas contra cd40 y sus usos
TW200738748A (en) Human monoclonal antibody human CD134 (OX40) and methods of making and using same
PE20080119A1 (es) Anticuerpos anti-5ta y sus usos
HRP20110203T1 (en) Improved protofibril selective antibodies and the use thereof
PE20080187A1 (es) Agonistas receptores de eritropoietina
PE20140247A1 (es) Anticuerpos anti-cd38
ITMI20031127A1 (it) Anticorpi anti-hgf-r e loro uso
ES2625823T3 (es) Anticuerpo anti-FGF23 y composición farmacéutica que comprende el mismo
NZ595863A (en) Antibodies to egfl7 and methods for their use
DK1987357T3 (da) Polypeptider, som genkendes af anti-Trichinella-antistoffer, og anvendelser deraf
DOP2005000210A (es) Antibony formulations